Harvey Lieberman

Title: Harvey Lieberman: Innovator in Pharmaceutical Formulations

Introduction

Harvey Lieberman is a notable inventor based in Bridgewater, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of formulations for tropomyosin-related kinase (TRK) inhibitors. With a total of 4 patents to his name, Lieberman's work is paving the way for advancements in targeted therapies.

Latest Patents

Lieberman's latest patents focus on pharmaceutical formulations of tropomyosin-related kinase (TRK) inhibitors. These formulations include 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form. This form demonstrates improved characteristics over the anhydrate form and is also available in extended-release formulations. The extended-release pharmaceutical formulations consist of 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.

Career Highlights

Harvey Lieberman is currently associated with Genzyme Corporation, where he continues to innovate in the pharmaceutical sector. His expertise in drug formulation has been instrumental in developing effective therapies for various medical conditions.

Collaborations

Lieberman has collaborated with notable colleagues such as Donglai Yang and C. Michael Philbrook. These partnerships have contributed to the successful development of his patented formulations.

Conclusion

Harvey Lieberman's work in pharmaceutical formulations showcases his dedication to advancing medical science. His innovative contributions are essential for the future of targeted therapies.